We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+50.65%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$5.42B
AUM Growth
+$1.85B
Cap. Flow
+$509M
Cap. Flow %
9.4%
Top 10 Hldgs %
46.89%
Holding
89
New
20
Increased
11
Reduced
36
Closed
9

Top Buys

1
ADCT icon
ADC Therapeutics
ADCT
+$210M
2
BNTX icon
BioNTech
BNTX
+$145M
3
IMMU
Immunomedics Inc
IMMU
+$102M
4
PLRX icon
Pliant Therapeutics
PLRX
+$90.5M
5
RPTX
Repare Therapeutics
RPTX
+$76.6M

Top Sells

1
BIIB icon
Biogen
BIIB
+$128M
2
QURE icon
uniQure
QURE
+$90.1M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$75.7M
4
TNDM icon
Tandem Diabetes Care
TNDM
+$56.7M
5
CNC icon
Centene
CNC
+$49M

Sector Composition

1 Healthcare 93.05%
2 Industrials 1.02%
3 Financials 0.23%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRS
76
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.26M 0.04%
21,229
– –
VAPO
77
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$1.02M 0.02%
3,125
– –
OVID icon
78
Ovid Therapeutics
OVID
$455M
$899K 0.02%
121,950
– –
ELGX
79
DELISTED
Endologix Inc
ELGX
$63K ﹤0.01%
78,755
– –
CSLT
80
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$8K ﹤0.01%
10,229
– –
ADPT icon
81
Adaptive Biotechnologies
ADPT
$3.63B
– –
-414,400
Closed -$11.5M
CNC icon
82
Centene
CNC
$32.7B
– –
-824,090
Closed -$49M
CBIO
83
Crescent Biopharma
CBIO
$407M
– –
-2,535
Closed -$578K
GOSS icon
84
Gossamer Bio
GOSS
$82.3M
– –
-259,700
Closed -$2.64M
RVMD icon
85
Revolution Medicines
RVMD
$39.3B
– –
-303,371
Closed -$6.65M
TNDM icon
86
Tandem Diabetes Care
TNDM
$1.15B
– –
-881,266
Closed -$56.7M
SWAV
87
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
– –
-557,800
Closed -$18.5M
SGEN
88
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-655,700
Closed -$75.7M
CLVS
89
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-99,485
Closed -$633K
1 2 3
4

Similar funds

ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return

Redmile Group's Q2 2020 Portfolio in Review

As of Q2 2020, Redmile Group held 89 positions worth $5.42B, up 52% from $3.57B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Redmile Group deployed $509M of net new capital in Q2 2020, opening 20 new positions and adding to 11 existing holdings. Its largest new stake was ADC Therapeutics: 5,525,870 shares worth $259M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 98% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was Biogen, an estimated $128M trimmed.

  • Redmile Group's largest Q2 2020 buy was ADC Therapeutics: 5,525,870 shares worth $259M.
  • Redmile Group added most to BioNTech in Q2 2020, an estimated $145M increase.
  • Redmile Group's biggest Q2 2020 reduction was Biogen, cutting an estimated $128M.
  • Redmile Group fully exited Seagen Inc. Common Stock in Q2 2020, selling an estimated $75.7M.
  • Redmile Group's ten largest holdings make up 47% of its $5.42B portfolio in Q2 2020.
  • Redmile Group opened 20 new positions and closed 9 in Q2 2020.
  • Redmile Group's portfolio value rose 52% quarter-over-quarter to $5.42B.

Based on Redmile Group's 13F filing for Q2 2020, filed 14 Aug 2020.